Florence Sens, Maurice Laville, Laure Groisne, David Ciabrini
{"title":"[New s in nephroprotection].","authors":"Florence Sens, Maurice Laville, Laure Groisne, David Ciabrini","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>NEWS IN NEPHROPROTECTION. Nephroprotection aims to preserve kidney function and slow the progression of chronic kidney disease. Recent decades have been marked by an expansion of therapeutic options, likely to reduce the number of patients reaching the stage of end-stage renal failure. Among these advances, inhibitors of sodium-glucose cotransport type II (iSGLT2), glucagon like peptide-1 analogues and non-steroidal mineralocorticoid receptor antagonists occupy a central place, in addition to conventional strategies, such as hygienic-dietary measures and blockers of the renin-angiotensin-aldosterone system. This article provides an overview of recent advances in the field of cardio-nephroprotection of adult patients with chronic kidney disease, with particular emphasis on the role and conditions of use of iSGLT2, also called gliflozins.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"239-246"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception for adolescent].","authors":"Anna Gosset","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION FOR ADOLESCENT. Adolescence is a key time to educate patients about sexual health and contraception. Decision-making should be shared and should consider the effectiveness of contraception, particularly related to expected adherence, secondary benefits, and risk factors. Long-acting reversible contraceptives (LARC) can be used as a first-line option due to their effectiveness. Common issues during adolescence, such as dysmenorrhea and heavy uterine bleeding, can be improved with hormonal contraception. The prescription of estrogen-progestin contraception should be preceded by a thorough assessment of arterial and venous risk factors.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"270-275"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception and acne].","authors":"Hortense Baffet","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION AND ACNE. Acne is one of the most common disorders of young women during their genital activity. Although its pathophysiology is complex, acne seems to be partly linked to increased sensitivity to androgens. Hormonal contraception (estrogen-progestin or progestin-only) has therefore a positive or negative impact on acne, which varies according to the type of estrogen/progestin molecule or combination used. The management of acne is well codified according to its grade in the 2015 Société française de dermatologie (SFD) recommendations. Nevertheless, it's important to remember that hormonal contraception alone is not part of acne therapy. On the other hand, in the case of acne-prone women wishing to use contraception, combined oral contraceptives with a low venous thromboembolic risk should be preferred, as should those containing an anti-androgenic progestogen, particularly norgestimate, which meets both requirements.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"279-285"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception and thrombophilia].","authors":"Geneviève Plu-Bureau, Brigitte Raccah-Tebeka","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION AND THROMBOPHILIA. The term thrombophilia includes two different aspects to be considered: the biological aspect with the existence of a hemostasis anomaly activating coagulation and increasing the risk of venous thromboembolic event (VTE), and the clinical aspect with the existence of a first-degree relative having had a venous thromboembolic event at a young age. Systematic screening for biological thrombophilia is not recommended before prescribing hormonal contraception in the absence of a family history or personal event, as it is probably not cost-effective. All combined hormonal contraceptives, whatever the route of administration (oral, patch or vaginal ring) or type of estrogen, are contraindicated in women with biological thrombophilia. Injectable progestin contraception with medroxyprogesterone acetate is also contraindicated. All other contraceptives strategies are authorized: copper or levonorgestrel intrauterine devices (IUD), progestin-only pills, subcutaneous implants, definitive contraception in the case of a completed parental project.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"290-292"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception et VIH].","authors":"Mathilde Latour","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION AND HIV. While the use of condoms is the only contraceptive method that also protects against the sexual transmission of HIV, it is common practice to combine it with another contraceptive method to minimise the risks of an unplanned pregnancy. According to the latest international recommendations, all contraceptive methods are authorised in cases of HIV infection in accordance with their usual precautions for use (risk factors, drug interactions, tolerance, etc.).</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"300-302"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Roles of coordination support systems].","authors":"Sophie Favé, Asma Fares, Annabelle Bernal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>ROLE OF COORDINATION SUPPORT SYSTEMS. The concepts of healthcare pathway and territory are at the heart of local healthcare provision. Some patients require specific support, given their risk factors and social vulnerability. Legislation relating to complex healthcare pathways has evolved, with local services supporting healthcare professionals. Healthcare pathways include the medical, psychological, social and environmental needs of each patient. New coordination support facilities is to help practitioners in their care in order to refocus them on their core specialty, in a patient-centered approach. The pooling of different skills of primary care medicine and medico-social support services is possible to provide personalized responses for the most vulnerable people, whose action strategies are not exclusively medical.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"255-257"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception after forty].","authors":"Marie Lambert","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION AFTER FORTY. The prescription of contraception after the age of 40 should be discussed with each woman because fertility and pregnancy's risk still exist. It requires a thorough evaluation of the situation, to identify any vascular and metabolic risk factors. No method of contraception is contraindicated by age alone. However, because age is a risk factor for vascular and metabolic diseases, combined hormonal contraception and injectable progestins should not be prescribed at first intention. Long-acting reversible contraception, sterilization and progestin-only pills have to be prescribed as first-line.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"276-278"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contraception and migraine].","authors":"Lorraine Maitrot-Mantelet, Geneviève Plu-Bureau","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CONTRACEPTION IN MIGRAINOUS PATIENT. Before any prescription or renewal of the combined hormonal contraception (CHC), screen for migraine, with or without aura, in addition to evaluation of the main arterial risk factors, is essential. In women with migraine without aura, CHC can be prescribed in the absence of any other arterial risk factor. In case of migraine with aura or in case of migraine without aura when any arteriel risk factor is present, CHC is contraindicated and progestin only pill or non-hormonal contraception should be prescribed. In women with bothersome menstrual migraine who are already under hormonal contraception, continuous intake or shortened hormone-free interval should be proposed.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"286-289"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
